Your browser doesn't support javascript.
loading
Impact of Poloxamer 188 Material Attributes on Proteinaceous Visible Particle Formation in Liquid Monoclonal Antibody Formulations.
Soeda, Kohei; Fukuda, Masakazu; Takahashi, Masaya; Imai, Hirotaka; Arai, Kengo; Saitoh, Satoshi; Kishore, Ravuri S K; Oltra, Nuria Sancho; Duboeuf, Jeremy; Hashimoto, Daisuke; Yamanaka, Yuji.
Afiliación
  • Soeda K; Formulation Development Department, Chugai Pharmaceutical Co., Ltd., 5-5-1 Ukima, Kita-ku, Tokyo 115-8543, Japan.
  • Fukuda M; Formulation Development Department, Chugai Pharmaceutical Co., Ltd., 5-5-1 Ukima, Kita-ku, Tokyo 115-8543, Japan. Electronic address: fukuda.masakazu76@chugai-pharm.co.jp.
  • Takahashi M; Quality Development Department, Chugai Pharma Manufacturing Co., Ltd., 5-5-1 Ukima, Kita-ku, Tokyo 115-8543, Japan.
  • Imai H; Quality Development Department, Chugai Pharma Manufacturing Co., Ltd., 5-5-1 Ukima, Kita-ku, Tokyo 115-8543, Japan.
  • Arai K; Formulation Development Department, Chugai Pharmaceutical Co., Ltd., 5-5-1 Ukima, Kita-ku, Tokyo 115-8543, Japan.
  • Saitoh S; Quality Development Department, Chugai Pharma Manufacturing Co., Ltd., 5-5-1 Ukima, Kita-ku, Tokyo 115-8543, Japan.
  • Kishore RSK; F. Hoffmann-La Roche Ltd., Pharmaceutical Development & Supplies, Pharma Technical Development Biologics Europe, Grenzacherstrasse 124, 4070 Basel, Switzerland.
  • Oltra NS; F. Hoffmann-La Roche Ltd., Pharmaceutical Development & Supplies, Pharma Technical Development Biologics Europe, Grenzacherstrasse 124, 4070 Basel, Switzerland.
  • Duboeuf J; F. Hoffmann-La Roche Ltd., Pharmaceutical Development & Supplies, Pharma Technical Development Biologics Europe, Grenzacherstrasse 124, 4070 Basel, Switzerland.
  • Hashimoto D; Formulation Development Department, Chugai Pharmaceutical Co., Ltd., 5-5-1 Ukima, Kita-ku, Tokyo 115-8543, Japan.
  • Yamanaka Y; Formulation Development Department, Chugai Pharmaceutical Co., Ltd., 5-5-1 Ukima, Kita-ku, Tokyo 115-8543, Japan.
J Pharm Sci ; 111(8): 2191-2200, 2022 08.
Article en En | MEDLINE | ID: mdl-35461805
Surfactants such as Poloxamer 188 (PX188) play an important role in controlling particle formation in biotherapeutic formulations due to interfacial stresses. This study demonstrates for the first time that hydrophobicity of PX188 is a potential critical material attribute (CMA) as far as control of visible particle (VP) formation is concerned. We have found that within PX188 lots satisfying pharmacopeial specifications, there is variability in material attributes such as hydrophobicity, as determined from their reversed-phase high-performance liquid chromatography profiles. However, it currently remains unknown how such variability in hydrophobicity of PX188 affects surfactant function and VP formation. Here, we compared the effect of seven PX188 lots in two monoclonal antibody drug product formulations under various stress conditions. Notably, proteinaceous VP formation was reduced while using a PX188 lot with higher hydrophobicity. Our findings emphasize the importance of monitoring lot-to-lot variability of PX188 and provide insight into potential CMA for improving and controlling material attributes of PX188 for use in liquid biotherapeutic formulations.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Poloxámero / Anticuerpos Monoclonales Idioma: En Revista: J Pharm Sci Año: 2022 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Poloxámero / Anticuerpos Monoclonales Idioma: En Revista: J Pharm Sci Año: 2022 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Estados Unidos